Stock Screener App

Gratuito -

Installare

99.78

2.80% -2.91

Incyte Corp (INCY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Incyte Corp Borsa (INCY) Ultime notizie

Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer - Kalkine Media

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido - PharmiWeb.com

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced An - PharmiWeb.com

Japan Approves Incyte's (INCY) Zynyz for First-Line SCAC Treatme - GuruFocus

Incyte (INCY) Secures Japanese Approval for Minjuvi Combination Therapy - GuruFocus

New lymphoma drug combo in Japan keeps cancer from progressing longer - Stock Titan

New drug combo offers first-line option for advanced anal cancer in Japan - Stock Titan

Entry Recap: Can Incyte Corporation stock beat market expectations this quarterJuly 2025 Snapshot & Weekly Top Gainers Trade List - moha.gov.vn

Incyte’s Precision Antibody Delivers Striking Results in Rare Blood Cancer - MyChesCo

Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

VP Iyengar Files To Sell 52,941 Of Incyte Corp [INCY] - TradingView — Track All Markets

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Why Incyte Corporation (ICY) stock stays on buy listsMarket Performance Report & High Conviction Buy Zone Alerts - DonanımHaber

Can Incyte Corporation stock hit analyst price targetsWatch List & Free Weekly Watchlist of Top Performers - DonanımHaber

Michael James Morrissey Sells 4,323 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat

Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally - Yahoo Finance

First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY) - simplywall.st

Incyte Corp EVP Sells Over $5.6 Million in Company Stock - TradingView — Track All Markets

EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi - Yahoo Finance

Incyte to Present at Upcoming Investor Conference - Business Wire

EC approves Incyte’s Minjuvi combo for follicular lymphoma - Pharmaceutical Technology

Incyte wins European approval of Minjuvi in FL - The Pharma Letter

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - BioSpace

Incyte's Minjuvi Gets Second Nod From EC For R/R Follicular Lymphoma - Nasdaq

Incyte (INCY) Gains EU Approval for Minjuvi in Follicular Lympho - GuruFocus

Minjuvi approved in EU for relapsed follicular lymphoma treatment - Investing.com

Incyte (INCY) Gains European Approval for Minjuvi in New Cancer Treatment - GuruFocus

Incyte announces EU approval of Xencor-partnered lymphoma therapy - Seeking Alpha

Minjuvi approved in EU for relapsed follicular lymphoma treatment By Investing.com - Investing.com South Africa

INCYTE wins European approval for Minjuvi cancer treatment - StreetInsider

(tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire

Is Incyte’s 2025 Surge Justified by Cash Flow Outlook and Oncology Pipeline Progress? - simplywall.st

VP Morrissey Files To Sell 54,008 Of Incyte Corp [INCY] - TradingView — Track All Markets

Is Incyte Corp Gaining or Losing Market Support? - Sahm

Incyte (INCY): Reassessing Valuation After Breakthrough Therapy Status and Positive INCA033989 Phase 1 Data - simplywall.st

Shareholder Stamoulis Files To Sell 187,690 Of Incyte Corp [INCY] - TradingView — Track All Markets

Palmetto Grain Brokerage - Palmetto Grain Brokerage

Is Incyte Stock Outperforming the Nasdaq? - Yahoo Finance

Incyte Lures New Top Lawyer With Hefty Equity Package Tied to Performance - MyChesCo

Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY - MarketBeat

Incyte Corporation (INCY) Announces Retirement of Board Member H - GuruFocus

Incyte director Hervé Hoppenot retires from board effective immediately By Investing.com - Investing.com Canada

Incyte Corp EVP & Chief Scientific Officer Sells Shares - TradingView — Track All Markets

Incyte director Hervé Hoppenot retires from board effective immediately - Investing.com

Incyte Corp Announces Board Retirement - TradingView — Track All Markets

Hervé Hoppenot resigns from Incyte’s board of directors - Investing.com

Incyte Announces Change to its Board of Directors - Business Wire

WINTON GROUP Ltd Makes New Investment in Incyte Corporation $INCY - MarketBeat

Ieq Capital LLC Has $27.52 Million Position in Incyte Corporation $INCY - MarketBeat

Incyte’s Blood Cancer Drug Shows Promise, But Hurdles Remain - Finimize

Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance

Incyte Corporation $INCY Shares Acquired by Investment Management Corp of Ontario - MarketBeat

Incyte stock rating reiterated by RBC, firm notes ’989 program viability - Investing.com

Jump Financial LLC Purchases 70,768 Shares of Incyte Corporation $INCY - MarketBeat

California Public Employees Retirement System Sells 122,593 Shares of Incyte Corporation $INCY - MarketBeat

Amundi Purchases 101,220 Shares of Incyte Corporation $INCY - MarketBeat

Incyte releases data that shows promise in treating rare blood disease - Delaware Business Now

Sun Pharma Claims New Pill Distinct From Incyte's Hit Drug - Law360

Incyte (NASDAQ:INCY) Upgraded at Mizuho - MarketBeat

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia - BioSpace

Incyte stock holds Market Perform rating at Citizens on CALR therapy lead - Investing.com

Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? - Yahoo Finance

Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? - Yahoo Finance

Incyte (INCY) Reports Promising Phase 1 Results for INCA033989 i - GuruFocus

Incyte’s experimental drug shows strong response in blood disorder By Investing.com - Investing.com Canada

Incyte’s experimental drug shows strong response in blood disorder - Investing.com

Incyte presents data showing 90% response rate for blood cancer drug - StreetInsider

GMAB

$32.91

1.61%

BNTX

$93.16

0.75%

RPRX

$38.67

0.13%

ONC

$313.18

0.89%

INSM

$177.60

1.64%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters